|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>, ''World Health Organization''.</ref><ref>{{cite journal|year=2009|last1=López|first1=EL|last2=Contrini|first2=MM|last3=Glatstein|first3=E|last4=González Ayala|first4=S|last5=Santoro|first5=R|last6=Allende|first6=D|last7=Ezcurra|first7=G|last8=Teplitz|first8=E|last9=Koyama|first9=T|last10=Matsumoto|first10=Y.|last11=Sato|first11=H.|last12=Sakai|first12=K.|last13=Hoshide|first13=S.|last14=Komoriya|first14=K.|last15=Morita|first15=T.|last16=Harning|first16=R.|last17=Brookman|first17=S.|title=Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients|doi=10.1128/AAC.00343-09|journal=Antimicrobial agents and chemotherapy|pmid=19822704|volume=54|pages=239–243|issue=1|pmc=2798559|display-authors=8}}</ref> |
|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>, ''World Health Organization''.</ref><ref>{{cite journal|year=2009|last1=López|first1=EL|last2=Contrini|first2=MM|last3=Glatstein|first3=E|last4=González Ayala|first4=S|last5=Santoro|first5=R|last6=Allende|first6=D|last7=Ezcurra|first7=G|last8=Teplitz|first8=E|last9=Koyama|first9=T|last10=Matsumoto|first10=Y.|last11=Sato|first11=H.|last12=Sakai|first12=K.|last13=Hoshide|first13=S.|last14=Komoriya|first14=K.|last15=Morita|first15=T.|last16=Harning|first16=R.|last17=Brookman|first17=S.|title=Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients|doi=10.1128/AAC.00343-09|journal=Antimicrobial Agents and Chemotherapy|pmid=19822704|volume=54|pages=239–243|issue=1|pmc=2798559|display-authors=8}}</ref> |